The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Cytochrome P450 2E1 Genotype and the Susceptibility to Antituberculosis Drug–Induced Hepatitis
Open accessAbstract
Most cases with antituberculosis drug–induced hepatitis have been attributed to isoniazid. Isoniazid is metabolized by hepatic N–acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. However, the role of CYP2E1 in this hepatotoxicity has not yet been reported. The aim of this study was to evaluate whether the polymorphism of the CYP2E1 gene is associated with antituberculosis drug–induced hepatitis. A total of 318 tuberculosis patients who received antituberculosis treatment were followed prospectively. Their CYP2E1 and NAT2 genotypes were determined using a polymerase chain reaction with restriction fragment length polymorphism method. Twenty–one healthy volunteers were recruited for CYP2E1 phenotype study using a chlorzoxazone test. Forty–nine (15.4%) patients were diagnosed to have drug–induced hepatotoxicity. Patients with homozygous wild genotype CYP2E1 c1/c1 had a higher risk of hepatotoxicity (20.0%; odds ratio [OR], 2.52) than those with mutant allele c2 (CYP2E1 c1/c2 or c2/c2, 9.0%, P = .009). If CYP2E1 c1/c2 or c2/c2 genotype combined with rapid acetylator status was regarded as the reference group, the risk of hepatotoxicity increased from 3.94 for CYP2E1 c1/c1 with rapid acetylator status to 7.43 for CYP2E1 c1/c1 with slow acetylator status. After adjustment for acetylator status and age, the CYP2E1 c1/c1 genotype remained an independent risk factor for hepatotoxicity (OR, 2.38; P = .017). Furthermore, under the administration of isoniazid, the volunteers with CYP2E1 c1/c1 genotype had higher CYP2E1 activity than those with other genotypes had and, hence, might produce more hepatotoxins. In conclusion, CYP 2E1 genetic polymorphism may be associated with susceptibility to antituberculosis drug–induced hepatitis. (Hepatology 2003;37:924–930.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Performing the Exact Test of Hardy-Weinberg Proportion for Multiple Alleles
Guo, S. W., & Thompson, E. A. (1992) · Biometrics · doi:10.2307/2532296 · Cited by 4,880
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
Danan, G., & Benichou, C. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90101-6 · Cited by 1,481
Bass, J. B., Farer, L. S., Hopewell, P. C., O'Brien, R., Jacobs, R. F., Ruben, F., Snider, D. E., & Thornton, G. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.149.5.8173779 · Cited by 1,193
Criteria of drug-induced liver disorders
(1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90124-a · Cited by 1,106
Hayashi, S.-I., Watanabe, J., & Kawajiri, K. (1991) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a123619 · Cited by 666
Isoniazid Liver Injury: Clinical Spectrum, Pathology, and Probable Pathogenesis
MITCHELL, J. R., ZIMMERMAN, H. J., ISHAK, K. G., THORGEIRSSON, U. P., TIMBRELL, J. A., SNODGRASS, W. R., & NELSON, S. D. (1976) · Annals of Internal Medicine · doi:10.7326/0003-4819-84-2-181 · Cited by 505
Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Lai, S.-L., Yang, S.-Y., Chang, F.-Y., & Lee, S.-D. (2002) · Hepatology · doi:10.1053/jhep.2002.32102 · Cited by 432
Self-citationIsoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
De, K., Snider, D. E., & Caras, G. J. (1978) · PubMed · doi:10.1164/arrd.1978.117.6.991 · Cited by 368
Lee, W. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510263331706 · Cited by 305
Characterization of a major form of rat hepatic microsomal cytochrome P-450 induced by isoniazid.
Ryan, D. E., Ramanathan, L., Iida, S., Thomas, P. E., Haniu, M., Shively, J. E., Lieber, C. S., & Levin, W. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)88984-0 · Cited by 304
Bell, D. A., Taylor, J. A., Butler, M. A., Stephens, E. A., Wiest, J., Brubaker, L. H., Kadlubar, F. F., & Lucier, G. W. (1993) · Carcinogenesis · doi:10.1093/carcin/14.8.1689 · Cited by 292
Acharya, S. K., Dasarathy, S., Kumer, T. L., Sushma, S., Prasanna, K. S., Tandon, A., Sreenivas, V, Nijhawan, S., Panda, S. K., Nanda, S. K., et al. (1996) · Hepatology · doi:10.1002/hep.510230622 · Cited by 262
Activation of procarcinogens by human cytochrome P450 enzymes
Peter Guengerich, F., & Shimada, T. (1998) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(98)00037-2 · Cited by 260
Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
Pande, J. N., Singh, S. P., Khilnani, G. C., Khilnani, S., & Tandon, R. K. (1996) · Thorax · doi:10.1136/thx.51.2.132 · Cited by 244
Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
Wong, W.-M., Wu, P.-C., Yuen, M.-F., Cheng, C.-C., Yew, W.-W., Wong, P.-C., Tam, C.-M., Leung, C.-C., & Lai, C.-L. (2000) · Hepatology · doi:10.1002/hep.510310129 · Cited by 231
Watanabe, J., Hayashi, S.-I., & Kawajiri, K. (1994) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a124526 · Cited by 214
Oneta, C. M., Lieber, C. S., Li, J., Rüttimann, S., Schmid, B., Lattmann, J., Rosman, A. S., & Seitz, H. K. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00223-9 · Cited by 194
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A
Desta, Z., Soukhova, N. V., & Flockhart, D. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.2.382-392.2001 · Cited by 180
Yu, M.-W., Gladek-Yarborough, A., Chiamprasert, S., Santella, R. M., Liaw, Y.-F., & Chen, C.-J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90587-1 · Cited by 177
Stephens, E. A., Taylor, J. A., Kaplan, N., Yang, C.-H., Hsieh, L. L., Lucier, G. W., & Bell, D. A. (1994) · Pharmacogenetics · doi:10.1097/00008571-199408000-00002 · Cited by 169
Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics
Girre, C., Lucas, D., Hispard, E., Menez, C., Dally, S., & Menez, J.-F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90524-x · Cited by 162
Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans
Zand, R., Nelson, S. D., Slattery, J. T., Thummel, K. E., Kalhorn, T. F., Adams, S. P., & Wright, J. M. (1993) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1993.125 · Cited by 152
le Lucas, D., nez, C. M., Girre, C., Berthou, F. O., nez, P. B., Joannet, I., Hispard, É., Bardou, L., & nez, J.-F. O. M. (1995) · Pharmacogenetics · doi:10.1097/00008571-199510000-00005 · Cited by 150
Parthasarathy, R., Sarma, G. R., Janardhanam, B., Ramachandran, P., Santha, T., Sivasubramanian, S., Somasundaram, P. R., & Tripathy, S. P. (1986) · Tubercle · doi:10.1016/0041-3879(86)90003-6 · Cited by 150
Genetic polymorphisms of cytochrome P4502E1 related to the development of alcoholic liver disease
Tsutsumi, M., Takada, A., & Wang, J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90546-0 · Cited by 128
Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska, C., Hellström, P. E., & Fröseth, B. (1978) · PubMed · doi:10.1164/arrd.1978.118.3.461 · Cited by 109
Anti-tuberculosis medication and the liver: dangers and recommendations in management
Thompson, N., Caplin, M. E., Hamilton, M., Gillespie, S. H., Clarke, S. W., Burroughs, A. K., & McIntyre, N. (1995) · European Respiratory Journal · doi:10.1183/09031936.95.08081384 · Cited by 99
Inhibition of Isoniazid-Induced Hepatotoxicity in Rabbits by Pretreatment with an Amidase Inhibitor
Sarich, T. C., Adams, S. P., Petricca, G., & Wright, J. M. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38190-x · Cited by 95
Hwang, S., WU, J., LEE, C., Yen, F., Lu, C., LIN, T., & LEE, S. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00353.x · Cited by 91
Self-citationIsoniazid-rifampin-induced hepatitis in hepatitis B carriers
Wu, J., Lee, S., Yeh, P.-F., Chan, C., Wang, Y.-J., Huang, Y., Tsai, Y., Lee, P.-Y., Ting, L., & Lo, K. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90846-s · Cited by 87
Self-citationMaezawa, Y., Yamauchi, M., & Toda, G. (1994) · PubMed · Cited by 76
Elevated Serum Aminotransferase Induced by Isoniazid in Relation to Isoniazid Acetylator Phenotype
Yamamoto, T., Suou, T., & Hirayama, C. (1986) · Hepatology · doi:10.1002/hep.1840060223 · Cited by 66
Translational activation of ethanol-inducible cytochrome P450 (CYP2E1) by isoniazid
Park, K. S., Sohn, D. H., Veech, R. L., & Song, B. J. (1993) · European Journal of Pharmacology Environmental Toxicology and Pharmacology · doi:10.1016/0926-6917(93)90019-m · Cited by 61
Drug-induced liver disease in 2003
Pishvaian, A. C., Trope, B. W., & Lewis, J. H. (2004) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200405000-00005 · Cited by 41
Cited by
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review
Tostmann, A., Boeree, M. J., Aarnoutse, R. E., De Lange, W. C. M., Van Der Ven, A. J. A. M., & Dekhuijzen, R. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.05207.x · Cited by 781
Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management
Ramappa, V., & Aithal, G. P. (2013) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2012.12.001 · Cited by 508
Abboud, G., & Kaplowitz, N. (2007) · Drug Safety · doi:10.2165/00002018-200730040-00001 · Cited by 479
Metadata
- Authors
- Huang, Y.-S., Chern, H.-D., Su, W.-J., Wu, J.-C., Chang, S.-C., Chiang, C.-H., Chang, F.-Y., & Lee, S.-D.
- Venue
- Hepatology
- Published
- 2003-04
- Volume
- 37
- Issue
- 4
- Pages
- 924-930
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2039895358
- Cited by
- 426
- References
- 36
- FWCI
- 8.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.